Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Auteurs : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ Jaar : 2022 Journal : Prostate Cancer Prostatic Dis
CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.
Auteurs : Karam A, Mjaess G, Martinez Chanza N, Aoun F, Bou Kheir G, Younes H, Kazzi H, Albisinni S, Roumeguère T Jaar : 2022 Journal : Cancer Invest
Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.
Auteurs : Albisinni S, Martinez Chanza N, Aoun F, Diamand R, Mjaess G, Azzo JM, Esperto F, Bellmunt J, Roumeguère T, DE Nunzio C Jaar : 2021 Journal : Minerva Urol Nephrol
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
Auteurs : Epaillard N, Parent P, Loriot Y, Lavaud P, Vera-Cea EB, Martinez Chanza N, Rodriguez-Vida A, Dumont C, Lozano R, Llácer C, Ratta R, Oudard S, Thibault C, Auclin E Jaar : 2021 Journal : Front Oncol
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.
Auteurs : Zambrana F, Carril-Ajuria L, Gómez de Liaño A, Martinez Chanza N, Manneh R, Castellano D, de Velasco G Jaar : 2021 Journal : Cancer Treat Rev